While targeting NF-κB has shown therapeutic potential in subgroups of blood cancer patients [21–26], heterogeneity and toxicities associated with global targeting of the canonical NF-κB pathway has challenged clinical progress. Here, NFKB1 is linked to hematopoietic and lymphoid system neoplasm.